LeeSSchwartzbergMD

Oncology • Germantown, TN

Professor, Medicine-Hematology, University of Tennessee Health Science Center College of Medicine

Join to view full profile

Dr. Schwartzberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Schwartzberg's full profile

Already have an account?

Office
7945 Wolf River Blvd
Germantown, TN 38138
Phone+1 901-683-0055

Fax+1 901-685-9718
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1983 - 1987
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1981 - 1983
New York Medical CollegeClass of 1980

Certifications & Licensure

NV State Medical License 2021 - 2025
AR State Medical License 2002 - 2023
MS State Medical License 1989 - 2022
TN State Medical License 1987 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2008-2014
Memphis Magazine: Top Doctors Castle Connolly, 2008-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013
Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2009-2012
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma Start of enrollment: 2001 Nov 01
Completed
Phase 2
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies Start of enrollment: 2005 Jun 01
Completed
Phase 1
1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy Start of enrollment: 2007 Jun 01
Completed
Phase 2
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer Start of enrollment: 2008 Aug 01
Completed
Phase 2
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations Start of enrollment: 2010 Feb 01
Completed
Phase 2
A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors Start of enrollment: 2011 Mar 01
Unknown status
Phase 1
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence Start of enrollment: 2011 Nov 01
Completed
Phase 3
Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2012 May 01
Unknown status
Phase 2
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) Start of enrollment: 2013 Oct 01
Terminated
Phase 2
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
Evaluation of a Mobile App to Promote Social Support for Oncology Patients Start of enrollment: 2020 Mar 12
Completed
Not Applicable
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative a...
Carlo Palmieri, Hannah Linden, Stephen N Birrell, Sally Wheelwright, Elgene Lim, Lee S Schwartzberg, Amy R Dwyer, Theresa E Hickey, Hope S Rugo, Patrick Cobb, Joyce A ...> ;The Lancet. Oncology. 2024 Mar 1
Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique.
Emily J Gallagher, Heather Moore, Mario E Lacouture, Susan F Dent, Azeez Farooki, Marcus D Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura...> ;NPJ Breast Cancer. 2024 Jan 31
Silent suffering: the impact of sexual health challenges on patient-clinician communication and adherence to adjuvant endocrine therapy among Black women with early-st...
Anderson, J., Paladino, A., Blue, R., Dangerfield, D., Eggly, S., Martin, M., Graetz, I., Schwartzberg, L., Vidal, G.> ;Journal of Cancer Survivorship. 2023 Dec 19
Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.
Lee Schwartzberg, Rudolph M Navari, Kathryn J Ruddy, Thomas W LeBlanc, Rebecca Clark-Snow, Rita Wickham, Dwight Kloth, Gary Binder, William L Bailey, Marco Turini, Rav...> ;Supportive Care in Cancer. 2023 Oct 25
2 citations
Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles.
Rudolph Navari, Gary Binder, Alex Molasiotis, Jørn Herrstedt, Eric J Roeland, Kathryn J Ruddy, Thomas W LeBlanc, Dwight D Kloth, Kelsey A Klute, Eros Papademetriou, Lu...> ;The Oncologist. 2023 Mar 17
4 citations
Mobile application to support oncology patients during treatment on patient outcomes: Evidence from a randomized controlled trial.
Ilana Graetz, Xin Hu, Andrea N Curry, Andrew Robles, Gregory A Vidal, Lee S Schwartzberg> ;Cancer Medicine. 2023 Mar 1
2 citations
Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor-Positive Breast Cancer.
Xin Hu, Cameron M Kaplan, Michelle Y Martin, Mark S Walker, Edward Stepanski, Lee S Schwartzberg, Gregory A Vidal, Ilana Graetz> ;Cancer Epidemiology, Biomarkers & Prevention. 2023 Feb 6
1 citations
An examination of health care utilization during the COVID-19 pandemic among women with early-stage hormone receptor-positive breast cancer.
Andrew J Paladino, Kinsey Pebley, Mehmet Kocak, Rebecca A Krukowski, Teresa M Waters, Gregory Vidal, Lee S Schwartzberg, Andrea N Curry, Ilana Graetz> ;BMC Health Services Research. 2022 Nov 23
3 citations
Molecular characterization of ESR1 variants in breast cancer.
Arielle L Heeke, Andrew Elliott, Rebecca Feldman, Hazel F O'Connor, Paula R Pohlmann, Filipa Lynce, Sandra M Swain, Maria R Nunes, Daniel Magee, Matthew J Oberley, Jef...> ;Breast Cancer Research and Treatment. 2022 Nov 1
9 citations
Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review.
Douglas W Blayney, Lee Schwartzberg> ;Cancer Treatment Reviews. 2022 Sep 1
12 citations
Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC.
Lee S Schwartzberg, Gerald Li, Khaled Tolba, Ariel B Bourla, Katja Schulze, Rujuta Gadgil, Alexander Fine, Katherine T Lofgren, Ryon P Graf, Geoffrey R Oxnard, Davey D...> ;JTO Clinical and Research Reports. 2022 Sep 1
10 citations
Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.
Xin Hu, Mark S Walker, Edward Stepanski, Cameron M Kaplan, Michelle Y Martin, Gregory A Vidal, Lee S Schwartzberg, Ilana Graetz> ;JAMA Network Open. 2022 Aug 1
10 citations
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an Int...
Bolivar Arboleda, Rupert Bartsch, Evandro de Azambuja, Erika Hamilton, Nadia Harbeck, Jennifer Klemp, Michael Knauer, Sherko Kuemmel, Reshma Mahtani, Lee Schwartzberg,...> ;The Oncologist. 2022 Sep 2
4 citations
Social Disparities of Pain and Pain Intensity Among Women Diagnosed With Early Stage Breast Cancer.
Hyo Young Choi, Ilana Graetz, Arash Shaban-Nejad, Lee Schwartzberg, Gregory Vidal, Robert Lowell Davis, Eun Kyong Shin> ;Frontiers in Oncology. 2022 Jan 1
2 citations
Impact of early detection on cancer curability: A modified Delphi panel study.
Lee Schwartzberg, Michael S Broder, Sikander Ailawadhi, Himisha Beltran, L Johnetta Blakely, G Thomas Budd, Laurie Carr, Michael Cecchini, Patrick Cobb, Anuraag Kansal...> ;Plos One. 2022 Jan 1
8 citations
Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexistin...
Karen A. Gelmon, Janice M. Walshe, Reshma Mahtani, Anil A. Joy, Meghan Sri Karuturi, Patrick Neven, D. Lu, Sindy T. Kim, Patrick Schnell, Eustratios Bananis, Lee S. Sc...> ;Breast. 2021 Jul 28
2 citations
Healthcare resource utilization and cost among patients treated for early-stage triple-negative breast cancer.
Amin Haiderali, Whitney C Rhodes, Santosh Gautam, Min Huang, Jan Sieluk, Karen E Skinner, Lee S. Schwartzberg> ;Future Oncology. 2021 Jul 13
1 citations
Real-world treatment patterns and effectiveness outcomes in patients with early-stage triple-negative breast cancer.
Amin Haiderali, Whitney C Rhodes, Santosh Gautam, Min Huang, Jan Sieluk, Karen E Skinner, Lee S. Schwartzberg> ;Future Oncology. 2021 Jul 6
5 citations
Comparison of Chemotherapy vs Chemotherapy Plus Total Hysterectomy for Women With Uterine Cancer With Distant Organ Metastasis.
Yuefeng Wang, Todd Tillmanns, Noam A. VanderWalde, Bradley G. Somer, Ari M. Vanderwalde, Lee S. Schwartzberg, Matthew T. Ballo> ;JAMA Network Open. 2021 Jul 1
4 citations
Characterization of Clinical Symptoms by Race Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Before Starting Chemotherapy.
Xin Hu, Puneet Kaur Chehal, Cameron M. Kaplan, Rebecca A. Krukowski, Roy H. Lan, Edward J. Stepanski, Lee S. Schwartzberg, Gregory A. Vidal, Ilana Graetz> ;JAMA Network Open. 2021 Jun 1
3 citations
Time to Rethink the Role of Clinical Pathways in the Era of Precision Medicine: A Lung Cancer Case Study
Stephen M. Schleicher, Basit Iqbal Chaudhry, Natalie R. Dickson, Emeline M. Aviki, Edward Arrowsmith, Ravi B. Parikh, Andrew Yue, Nora Connor, Lee S. Schwartzberg, Aar...> ;JCO Oncology Practice. 2021 Apr 19
5 citations
Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation.
Lee S. Schwartzberg, Lesli A. Kiedrowski> ;Therapeutic Advances in Medical Oncology. 2021 Apr 5
1 citations
Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes.
Andrew Elliott, Michelle Saul, Jia Zeng, John L. Marshall, Edward S. Kim, Misako Nagasaka, Heinz-Josef Lenz, Lee S. Schwartzberg, David Spetzler, Jim Abraham, Joanne X...> ;Scientific Reports. 2021 Mar 11
10 citations
Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer.
Karen E Skinner, Amin Haiderali, Min Huang, Lee S. Schwartzberg> ;Future Oncology. 2021 Mar 1
7 citations
Assessing direct costs of treating metastatic triple-negative breast cancer in the USA.
Karen E Skinner, Amin Haiderali, Min Huang, Lee S. Schwartzberg> ;Journal of Comparative Effectiveness Research. 2021 Feb 1
Join now to see all

Abstracts/Posters

Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United St...
Lee S. Schwartzberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Eflapegrastim, a novel and potent long-acting GCSF for reducing chemotherapy-induced neutropenia: Integrated results from two phase III trials in breast cancer patients.
2019 ASCO Annual Meeting - 6/1/2019
Safety of intravenous (IV) NEPA and oral NEPA for prevention of CINV in patients (pts) with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemothera...
2019 ASCO Annual Meeting - 6/1/2019
7th Community Oncology Conference
Global Academy for Medical Education (Elsevier), Las Vegas, Nevada - 3/30/2012

Press Mentions

Freenome Adds Renown Health as Partner for the Sanderson StudyMarch 28th, 2023
Growing PainsApril 8th, 2022
OneOncology Unveils Data Demonstrating Increased Utilization of Genomic and Biomarker Testing at Community Cancer CentersSeptember 27th, 2021
Join now to see all